Treating cryptococcal meningitis in people with HIV
Part of Brain & nervous system, Immune system & allergy, Infections clinical trials.
This trial is testing new treatments for cryptococcal meningitis, a serious brain infection, in people living with HIV. It aims to find the best way to treat this infection with fewer side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a positive test for cryptococcal meningitis in your spinal fluid.
- You are living with HIV.
- You are 18 years or older.
- You are willing to have lumbar punctures (spinal taps) as part of this trial.
- You have not had more than 2 doses of antifungal treatment for meningitis in the last 30 days.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a one-time antifungal treatment can help people with HIV who have a positive cryptococcal antigen blood test but no symptoms. It may lower the chance that this infection becomes a serious illness affecting the brain.
This study tests a shorter course of an antifungal medicine (fluconazole) for people with HIV who have a low level of a fungus called cryptococcus in their blood. The goal is to see if a shorter treatment works as well and to find the best time to start HIV medicines.
This trial tests the drug amphotericin B for people with cryptococcal meningitis who do not have HIV. The goal is to see if this treatment is safe and effective.
This study compares two different HIV medication regimens in people who have both HIV and active tuberculosis (TB) and are starting HIV treatment for the first time. The goal is to see which combination works better and is safer when taken together with TB medications.
This trial tests a single high dose of a potent antifungal medicine (liposomal amphotericin B) combined with a modern HIV treatment (B/F/TAF) for people with HIV who have a serious fungal infection called talaromycosis. The goal is to see if this short, powerful treatment works well and is safe.
This study tests whether a combination of two antifungal drugs works well for treating talaromycosis, a serious fungal infection common in people with HIV. The goal is to find a more convenient and effective treatment.
Hear when a new HIV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.